• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

    6/28/21 7:10:00 PM ET
    $IOVA
    $BBIO
    $EIDX
    $BMEA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IOVA alert in real time by email

    REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining.

    Recently, Mr. Valle served as Principal Accounting Officer & Senior Vice President of Finance at Eidos (NASDAQ:EIDX), a former publicly traded, clinical-stage biopharmaceutical company, which merged with BridgeBio (NASDAQ:BBIO) for $2.83 Billion earlier in 2021. Prior to Eidos, Mr. Valle served as the Principal Accounting Officer and Controller at Iovance Biotherapeutics (NASDAQ:IOVA) from 2016 until 2018. Mr. Valle also worked at Pharmacyclics , which he joined in 2012 and supported through its merger with Abbvie  as Senior Accounting Officer of the company. Mr. Valle is a certified public accountant and started his career in 2005 at Pricewaterhouse Coopers LLP, where he spent six years in the Life Science, Biotech and Venture Capital Group.

    "I am really excited to welcome Franco to our leadership team," said Tom Butler, Biomea's CEO and Chairman of the Board. "His extensive experience in financial operations will help us build systems that will support our growth as we develop our pipeline of preclinical and clinical assets. We are on track to submit our IND to the FDA for BMF-219 during the second half of this year, and our strong balance sheet provides us ample funding not only to fully explore BMF-219 in multiple tumor types, but also to build out our proprietary irreversible platform, and progress multiple earlier stage pipeline molecules into the clinic. On behalf of the entire Biomea team, I welcome Franco and look forward to his contributions."

    "I have worked together with Franco in the past, and I could not be happier he joined as the CFO of Biomea," said Eric Aguiar, M.D., Lead Director and Chairman of the Audit Committee at Biomea. "Franco is very knowledgeable, structured, and will help Biomea continue to build organizational systems to grow and support the full clinical exploration of Biomea's portfolio of small molecules."

    "I am thrilled to join Biomea, particularly on the heels of its successful IPO in April and strong pipeline of clinical catalysts. I have worked with many of the leadership in the past and know first-hand their track record and commitment to develop novel irreversible small molecules that transform treatments in a targeted, patient friendly manner," said Mr. Valle.

    Mr. Valle will be joined by Terrie Phan, who will become Vice President and Corporate Controller of Biomea. Ms. Phan is also a licensed CPA and has worked most of her career supporting growth-oriented biotech companies, serving as a Controller, expert Accounting Manager as well as a Financial Planner and SOX Compliance Manager. Mr. Valle will assume the financial leadership from Sunny Lee. The company thanks Ms. Lee for her contributions and support during the IPO process and the transition from being a private company to a public corporation.

    About Biomea Fusion

    Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. An irreversible small molecule drug is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging its extensive expertise in irreversible binding chemistry and development, the Company built its proprietary FUSION System discovery platform to advance a pipeline of novel irreversible, small molecule therapies. The lead product candidate, BMF-219, is an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. In preclinical studies, administration of BMF-219 has resulted in robust anti-tumor responses across a range of liquid and solid tumor models and has been well-tolerated in animal studies. Biomea Fusion is developing BMF-219 for the treatment of liquid and solid tumors that are highly dependent on menin, including leukemias containing the mixed lineage leukemia ("MLL") fusion protein. The Company is currently completing investigational new drug ("IND") enabling studies and expects to file an IND application with the U.S. Food and Drug Administration in the second half of 2021. Beyond BMF-219, the Company is utilizing its novel platform to develop irreversible treatments against other high-value oncogenic drivers of cancer and expects to nominate its second development candidate in the first half of 2022. Biomea Fusion's goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential safety, efficacy, and continued development of BMF-219, the timing for completing the IND filing or starting the clinical development, the building out our proprietary irreversible platform and progress made in early-stage small pipeline molecules through their preclinical development, including the timing for nominating development candidates in each program. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may," or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. Any forward-looking statements in this statement are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company's product candidate development activities and planned IND-enabling and clinical trials, the Company's ability to execute on its strategy, regulatory developments in the United States, the Company's ability to fund operations, and the impact that the current COVID-19 pandemic will have on the Company's clinical trials and pre-clinical studies, supply chain, and operations, as well as those risks and uncertainties set forth in the Company's Quarterly Report on Form Q for the quarter ended March 31, 2021, filed with the Securities and Exchange Commission on May 27, 202, and its other filings filed with the United States Securities and Exchange Commission filed from time. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Biomea Contact:

    Ramses Erdtmann

    President - Biomea Fusion, Inc.

    [email protected]

    Phone: 805-455-1313



    Primary Logo

    Get the next $IOVA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IOVA
    $BBIO
    $EIDX
    $BMEA

    CompanyDatePrice TargetRatingAnalyst
    BridgeBio Pharma Inc.
    $BBIO
    6/17/2025$49.00Outperform
    Wolfe Research
    Biomea Fusion Inc.
    $BMEA
    6/3/2025$7.00Overweight
    Piper Sandler
    Iovance Biotherapeutics Inc.
    $IOVA
    5/16/2025$2.00Buy → Neutral
    UBS
    Iovance Biotherapeutics Inc.
    $IOVA
    5/12/2025Buy → Hold
    Truist
    Iovance Biotherapeutics Inc.
    $IOVA
    5/9/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    BridgeBio Pharma Inc.
    $BBIO
    3/31/2025$50.00Buy
    Redburn Atlantic
    Iovance Biotherapeutics Inc.
    $IOVA
    10/24/2024$17.00Buy
    UBS
    BridgeBio Pharma Inc.
    $BBIO
    10/16/2024Sector Outperform
    Scotiabank
    More analyst ratings

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    SEC Filings

    See more
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      7/3/25 4:05:53 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

      SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      7/1/25 7:49:36 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BridgeBio Pharma Inc.

      144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

      7/1/25 4:31:44 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    Leadership Updates

    Live Leadership Updates

    See more
    • Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

      Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202

      5/5/25 4:05:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

      Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported

      3/31/25 4:10:00 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    Financials

    Live finance-specific insights

    See more
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

      PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be a

      4/22/25 7:30:37 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

      - As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first

      2/20/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

      Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

      11/25/24 8:41:11 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

      For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

      2/16/24 3:48:47 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

      4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:49:25 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

      4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:46:18 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Kirby Daniel Gordon bought $55,200 worth of shares (30,000 units at $1.84) (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      6/6/25 4:05:31 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on BridgeBio Pharma with a new price target

      Wolfe Research initiated coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $49.00

      6/17/25 7:49:06 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Biomea Fusion with a new price target

      Piper Sandler resumed coverage of Biomea Fusion with a rating of Overweight and set a new price target of $7.00

      6/3/25 7:31:50 AM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iovance Biotherapeutics downgraded by UBS with a new price target

      UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00

      5/16/25 8:01:50 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

      BridgeBio has received a $300 million upfront payment, strengthening the Company's balance sheet, and supporting the launch of Attruby® and ongoing late-stage pipeline programsTransaction monetizes 60% of BridgeBio's European royalties on the first $500 million of annual BEYONTTRA net sales, with total payments to the investors subject to an initial cap of 1.45xIn the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients: In as few as 3 months, the time to first event (ACM or CVH) durably separated relative to placeboA 42% reduction in composite ACM and recurrent CVH events relative to placebo

      6/30/25 7:30:00 AM ET
      $BBIO
      $OWL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance
    • BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

      PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio. Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy (LGMD), specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKR

      6/26/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on June 20, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 312,660 shares of Iovance's common stock to 58 new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 2

      6/23/25 4:05:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Kumar Neil sold $3,410,450 worth of shares (80,000 units at $42.63) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      7/3/25 4:30:19 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Viking Global Investors Lp sold $154,000,000 worth of shares (3,500,000 units at $44.00) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      7/1/25 7:48:36 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Homcy Charles J gifted 20,000 shares, decreasing direct ownership by 2% to 1,216,674 units (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:54:20 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IOVA
    $BBIO
    $EIDX
    $BMEA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      11/14/24 4:50:30 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

      SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

      11/12/24 12:31:45 PM ET
      $BMEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      11/6/24 5:04:05 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care